WIL Research Contract Extension worth more than US$7million over four years
24 September 2014
Instem plc
("Instem" or the "Company")
WIL Research Contract Extension worth more than US$7million over four years
Instem’s products to be deployed by WIL Research at all of its sites worldwide
Instem (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, announces that WIL Research (“WIL”) has extended its order for the development of a comprehensive hosted solution to harmonise study-related processes at multiple sites worldwide.
This follows on from the announcement dated 01 May 2014 detailing WIL’s selection of Instem’s Provantis® and Centrus-submit™ solutions to replace and enhance its toxicology systems and processes worldwide. Following the successful initial phases of implementation, this contract extends the initial order to cover additional product modules and users, together with comprehensive implementation services.
The total contract value is expected to be in excess of US$7million over the next four years. The software licences are being purchased on a perpetual basis with Instem hosting the delivered solutions from a centralised state-of-the-art data centre.
WIL is a global contract research organisation (“CRO”) with approximately 1,300 staff and 63,000 square metres of laboratory space around the world. Its facilities offer a blend of technical and regulatory expertise in discovery support, product safety toxicological research, metabolism, bioanalytical, analytical chemistry, formulation and regulatory services.
The deployment will harmonise WIL’s global systems and processes creating a single common hosted environment with improved harmonisation and efficiencies for WIL and its clients. Instem will additionally reduce WIL’s use of paper-based data through the deployment of its Logbook™ ELN technology, replacing paper forms and control documents to help further increase productivity and accuracy. Centrus-submit will be an early priority in the implementation project, in anticipation of further FDA guidance on the Standard for the Exchange of Non-Clinical Data (SEND).
David Spaight, Chief Executive Officer at WIL Research, commented: “Instem’s solution will provide exactly what we need; harmonised data collection, integrated scheduling, cutting edge SEND management tools and global reporting to support key decision making across all of our departments. I am confident our expanded technology investment will enrich our research processes, help develop better controls and provide excellent experiences for every one of our clients while expanding our capabilities for continued growth.”
Phil Reason, CEO of Instem plc, commented: “We are delighted that, following a thorough evaluation, WIL has chosen to roll out our software across all of its sites worldwide. This clearly illustrates the confidence that another of the top five preclinical CROs has in our market leading technology and our SaaS delivery model. In addition, this contract will provide improved revenue visibility going forward.”
For further information, please contact:
| Instem plc | www.instem.com |
| Phil Reason, CEO | +44 (0) 1785 825600 |
| Nigel Goldsmith, CFO | |
| N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
| Richard Lindley | |
| Nick Owen | |
| James White | |
| Wallbrook Financial PR | Tel: +44 (0) 20 7933 8000 |
| Paul Cornelius | or instem@walbrookpr.com |
| Sam Allen | |
| Helen Cresswell | |
| Paul Whittington |
About WIL Research
WIL Research is an interdisciplinary non-clinical contract research organisation providing product safety, toxicological assessment research, bioanalytical, regulatory compliance / registration, formulation and manufacturing services to the international pharmaceutical, biotechnology, veterinary, industrial and agricultural chemical industries.
Find out more about WIL Research at www.wilresearch.com
About Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.
To learn more about Instem solutions and its mission, please visit instem.com.